Prognostic value of serum erythropoietin levels in late acute rejection of renal transplants. 1995

S Heidenreich, and M Tepel, and A Fahrenkamp, and K H Rahn
Department of Medicine, University of Münster, Germany.

Since renal allograft rejection is frequently associated with a blunted erythropoiesis, we investigated erythropoietin (EPO) serum concentrations in 17 patients with acute rejection, eight patients with chronic rejection, and 18 transplant recipients with stable graft function. All rejection episodes were proven by biopsy. Erythropoietin serum levels were significantly reduced in patients with chronic rejection (6.2 +/- 3.4 mU/mL; P < 0.01) compared with individuals with acute rejection (35.6 +/- 33.9 mU/mL) or stable graft function (24.0 +/- 19.7 mU/mL). Suppressed EPO levels were associated with marked anemia in chronic rejection patients. In a subgroup of patients with acute rejection and bad responses to an intensified immunosuppressive regimen or with transplant failure, we found significantly suppressed EPO levels (11.6 +/- 6.1 mU/mL) compared with a subgroup of patients with a beneficial acute rejection outcome (57.0 +/- 34.2 mU/mL; P < 0.01). A correlation between histologic parameters of acute rejection and hormone levels showed that signs of moderate glomerulitis were associated with elevated EPO levels, whereas lesions of moderate tubulitis were associated with low values. We conclude that serum EPO may have prognostic value for rejection outcome in renal transplant recipients.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000740 Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN. Anemias

Related Publications

S Heidenreich, and M Tepel, and A Fahrenkamp, and K H Rahn
August 1985, Transplantation proceedings,
S Heidenreich, and M Tepel, and A Fahrenkamp, and K H Rahn
May 1978, Revista clinica espanola,
S Heidenreich, and M Tepel, and A Fahrenkamp, and K H Rahn
February 1999, Transplantation,
S Heidenreich, and M Tepel, and A Fahrenkamp, and K H Rahn
June 1986, Transplantation,
S Heidenreich, and M Tepel, and A Fahrenkamp, and K H Rahn
February 1999, Orvosi hetilap,
S Heidenreich, and M Tepel, and A Fahrenkamp, and K H Rahn
August 2011, Kidney international supplements,
S Heidenreich, and M Tepel, and A Fahrenkamp, and K H Rahn
August 1977, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin,
S Heidenreich, and M Tepel, and A Fahrenkamp, and K H Rahn
January 1996, Transplant international : official journal of the European Society for Organ Transplantation,
S Heidenreich, and M Tepel, and A Fahrenkamp, and K H Rahn
June 2004, Clinical transplantation,
S Heidenreich, and M Tepel, and A Fahrenkamp, and K H Rahn
May 2007, The Journal of surgical research,
Copied contents to your clipboard!